Related Experiment Videos

Pharmacokinetics of LY163892 in infants and children

J D Nelson1, S Shelton, H Kusmiesz

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063.

Antimicrobial Agents and Chemotherapy
|November 1, 1988
PubMed

Insights

This study assessed LY163892 antibiotic concentrations in children. Higher doses led to increased peak levels and drug exposure, suggesting dose-dependent pharmacokinetics in pediatric populations.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Clinical Pharmacy

Background:

  • Understanding drug pharmacokinetics in pediatric populations is crucial for safe and effective treatment.
  • LY163892 is an antibiotic requiring pharmacokinetic evaluation in infants and children.

Purpose of the Study:

  • To determine the pharmacokinetic profile of LY163892 in pediatric patients.
  • To evaluate the safety and efficacy of different LY163892 dosages in infants and children.

Main Methods:

  • Two dosages of LY163892 (7.5 and 15 mg/kg) were administered to pediatric subjects.
  • Plasma specimens were collected over 4 hours post-administration for antibiotic assay.
  • Pharmacokinetic parameters including peak concentration, half-life, and area under the curve were calculated.

Main Results:

  • Peak plasma concentrations of 12.6 and 18.7 µg/mL were observed at 45 minutes for the lower and higher doses, respectively.
  • Mean half-lives were approximately 0.85 h and 0.78 h.
  • Mean areas under the curve (AUC) were 24.4 and 38.0 µg·h/mL, indicating greater drug exposure with the higher dosage.

Conclusions:

  • LY163892 exhibits dose-dependent pharmacokinetics in infants and children.
  • The observed pharmacokinetic profile supports further investigation into LY163892's therapeutic potential in pediatric infections.

Related Concept Videos